{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T03:22:15Z","timestamp":1789701735928,"version":"4.0.1"},"reference-count":24,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,22]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>In the phase 2 clinical trial (AIM) of venetoclax-ibrutinib, 24 patients with mantle cell lymphoma (MCL; 23 with relapsed\/refractory [R\/R] disease) received ibrutinib 560 mg and venetoclax 400 mg both once daily. High complete remission (CR) and measurable residual disease negative (MRD-negative) CR rates were previously reported. With median survivor follow-up now exceeding 7 years, we report long-term results. Treatment was initially continuous, with elective treatment interruption (ETI) allowed after protocol amendment for patients in MRD-negative CR. For R\/R MCL, the estimated 7-year progression-free survival (PFS) was 30% (95% confidence interval [CI], 14-49; median, 28 months; 95% CI, 13-82) and overall survival (OS) was 43% (95% CI, 23-62; median, 32 months; 95% CI, 15 to not evaluable). Eight patients in MRD-negative CR entered ETI for a median of 58 months (95% CI, 37-79), with 4 experiencing disease recurrence. Two of 3 reattained CR on retreatment. Time-to-treatment failure (TTF), which excluded progression in ETI for those reattaining response, was 39% overall and 68% at 7 years for responders. Beyond 56 weeks, grade \u22653 and serious adverse events were uncommon. Newly emergent or increasing cardiovascular toxicity were not observed beyond 56 weeks. We demonstrate long-term durable responses and acceptable toxicity profile of venetoclax-ibrutinib in R\/R MCL and show feasibility of treatment interruption while maintaining ongoing disease control. This trial was registered at www.clinicaltrials.gov as #NCT02471391.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2023023388","type":"journal-article","created":{"date-parts":[[2024,4,25]],"date-time":"2024-04-25T16:11:20Z","timestamp":1714061480000},"page":"867-872","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":27,"title":["Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions"],"prefix":"10.1182","volume":"144","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8790-4675","authenticated-orcid":false,"given":"Sasanka M.","family":"Handunnetti","sequence":"first","affiliation":[{"name":"1Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia"},{"name":"3Princess Alexandra Hospital, Brisbane, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3515-0215","authenticated-orcid":false,"given":"Mary Ann","family":"Anderson","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"4Cells and Blood Cancers, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6710-681X","authenticated-orcid":false,"given":"Kate","family":"Burbury","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"5The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2086-6031","authenticated-orcid":false,"given":"Philip A.","family":"Thompson","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"5The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glenda","family":"Burke","sequence":"additional","affiliation":[{"name":"6Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9718-9596","authenticated-orcid":false,"given":"Mathias","family":"Bressel","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia"},{"name":"6Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Di Iulio","sequence":"additional","affiliation":[{"name":"6Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0758-0824","authenticated-orcid":false,"given":"Rodney J.","family":"Hicks","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia"},{"name":"7Melbourne Theranostic Innovation Centre, Melbourne, Australia"},{"name":"8Centre for Cancer Research, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Westerman","sequence":"additional","affiliation":[{"name":"6Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6504-1343","authenticated-orcid":false,"given":"Stephen","family":"Lade","sequence":"additional","affiliation":[{"name":"6Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9260-8340","authenticated-orcid":false,"given":"Christiane","family":"Pott","sequence":"additional","affiliation":[{"name":"9University Hospital of Schleswig\u2013Holstein, Kiel, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishu","family":"Agarwal","sequence":"additional","affiliation":[{"name":"6Peter MacCallum Cancer Centre, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1627-8934","authenticated-orcid":false,"given":"Rachel","family":"Koldej","sequence":"additional","affiliation":[{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia"},{"name":"10ACRF Translational Research Laboratory, Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7329-6605","authenticated-orcid":false,"given":"David","family":"Ritchie","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia"},{"name":"10ACRF Translational Research Laboratory, Royal Melbourne Hospital, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0358-5249","authenticated-orcid":false,"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[{"name":"11LMU University Hospital, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5464-5029","authenticated-orcid":false,"given":"Mark A.","family":"Dawson","sequence":"additional","affiliation":[{"name":"5The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"6Peter MacCallum Cancer Centre, Melbourne, Australia"},{"name":"8Centre for Cancer Research, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8276-0374","authenticated-orcid":false,"given":"Sarah-Jane","family":"Dawson","sequence":"additional","affiliation":[{"name":"5The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia"},{"name":"6Peter MacCallum Cancer Centre, Melbourne, Australia"},{"name":"8Centre for Cancer Research, University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7341-5720","authenticated-orcid":false,"given":"Andrew W.","family":"Roberts","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"2Faculty of Medicine, Dentistry and Health Sciences, The University of Melbourne, Melbourne, Australia"},{"name":"4Cells and Blood Cancers, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9759-5017","authenticated-orcid":false,"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"1Department of Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Australia"},{"name":"12Alfred Hospital, Melbourne, Australia"},{"name":"13Monash University, Melbourne, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"8","key":"2024101113455509900_bib1","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1038\/s41375-018-0023-2","article-title":"Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study","volume":"32","author":"Rule","year":"2018","journal-title":"Leukemia"},{"issue":"1","key":"2024101113455509900_bib2","first-page":"343","article-title":"Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed\/refractory mantle cell lymphoma, including those with poor prognostic factors","volume":"109","author":"Le Gouill","year":"2024","journal-title":"Haematologica"},{"issue":"21","key":"2024101113455509900_bib3","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.2021014162","article-title":"Zanubrutinib in relapsed\/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study","volume":"139","author":"Song","year":"2022","journal-title":"Blood"},{"issue":"17","key":"2024101113455509900_bib4","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1158\/1078-0432.CCR-20-4842","article-title":"Long-term follow-up of patients with relapsed or refractory non-Hodgkin lymphoma treated with venetoclax in a phase 1, first-in-human study","volume":"27","author":"Davids","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"36","key":"2024101113455509900_bib5","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-risk mantle cell lymphoma: definition, current challenges, and management","volume":"38","author":"Jain","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"13","key":"2024101113455509900_bib6","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1182\/bloodadvances.2022008916","article-title":"A\u00a0multicentre analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma","volume":"7","author":"Sawalha","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2024101113455509900_bib7","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1182\/blood-2011-07-369629","article-title":"Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL database","volume":"119","author":"LaCasce","year":"2012","journal-title":"Blood"},{"issue":"48","key":"2024101113455509900_bib8","doi-asserted-by":"crossref","first-page":"6223","DOI":"10.1038\/onc.2016.155","article-title":"FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma","volume":"35","author":"Li","year":"2016","journal-title":"Oncogene"},{"issue":"11","key":"2024101113455509900_bib9","doi-asserted-by":"crossref","first-page":"8750","DOI":"10.18632\/oncotarget.3275","article-title":"Biological rational for sequential targeting of Bruton tyrosine kinase and Bcl-2 to overcome CD40-induced ABT-199 resistance in mantle cell lymphoma","volume":"6","author":"Chiron","year":"2015","journal-title":"Oncotarget"},{"issue":"5","key":"2024101113455509900_bib10","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/bjh.13149","article-title":"Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways","volume":"168","author":"Zhao","year":"2015","journal-title":"Br J Haematol"},{"issue":"13","key":"2024101113455509900_bib11","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1715519","article-title":"Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma","volume":"378","author":"Tam","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"2024101113455509900_bib12","doi-asserted-by":"crossref","first-page":"4849","DOI":"10.1182\/bloodadvances.2020002810","article-title":"Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapy","volume":"4","author":"Davis","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"2024101113455509900_bib13","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/S1470-2045(17)30012-8","article-title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"issue":"27","key":"2024101113455509900_bib14","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024101113455509900_bib15","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"2024101113455509900_bib16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1038\/s41591-018-0243-z","article-title":"Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma","volume":"25","author":"Agarwal","year":"2019","journal-title":"Nat Med"},{"issue":"2","key":"2024101113455509900_bib17","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"suppl 2","key":"2024101113455509900_bib18","article-title":"Ibrutinib combined with venetoclax in patients with relapsed\/refractory mantle cell lymphoma: primary analysis results from the randomized phase 3 Sympatico study [abstract]","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"issue":"suppl 2","key":"2024101113455509900_bib19","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1002\/hon.3164_352","article-title":"Long term follow-up of untreated\/relapsing MCL patients with ibrutinib, obinutuzumab, and venetoclax combination [abstract]","volume":"41","author":"Le Gouill","year":"2023","journal-title":"Hematol Oncol"},{"issue":"11","key":"2024101113455509900_bib20","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood-2018-11-886457","article-title":"A\u00a0phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma","volume":"133","author":"Martin","year":"2019","journal-title":"Blood"},{"issue":"7","key":"2024101113455509900_bib21","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(12)70200-0","article-title":"Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1\/2 clinical\u00a0trial","volume":"13","author":"Wang","year":"2012","journal-title":"Lancet Oncol"},{"issue":"3","key":"2024101113455509900_bib22","doi-asserted-by":"crossref","first-page":"e109","DOI":"10.1016\/S2352-3026(18)30018-8","article-title":"Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): a multicentre, open-label, single-arm, phase 2 trial","volume":"5","author":"Jerkeman","year":"2018","journal-title":"Lancet Haematol"},{"issue":"16","key":"2024101113455509900_bib23","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1182\/bloodadvances.2023009992","article-title":"Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma","volume":"7","author":"Phillips","year":"2023","journal-title":"Blood Adv"},{"issue":"9","key":"2024101113455509900_bib24","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1080\/10428194.2023.2223743","article-title":"Phase 2 trial of umbralisib, ublituximab, and venetoclax in patients with relapsed\/refractory mantle cell lymphoma","volume":"64","author":"Wallace","year":"2023","journal-title":"Leuk Lymphoma"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/8\/867\/2246396\/blood_bld-2023-023388-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/144\/8\/867\/2246396\/blood_bld-2023-023388-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,11]],"date-time":"2024-10-11T09:46:08Z","timestamp":1728639968000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/144\/8\/867\/515901\/Seven-year-outcomes-of-venetoclax-ibrutinib"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,22]]},"references-count":24,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2023023388","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,22]]}}}